Argentarii LLC Buys Shares of 3,293 Gilead Sciences, Inc. (NASDAQ:GILD)

Argentarii LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,293 shares of the biopharmaceutical company’s stock, valued at approximately $304,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC lifted its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Wellington Management Group LLP lifted its stake in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after purchasing an additional 5,653,075 shares during the period. Raymond James Financial Inc. purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $207,340,000. Finally, Point72 Asset Management L.P. increased its holdings in Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after acquiring an additional 1,793,145 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.2 %

Shares of GILD opened at $117.41 on Monday. The company has a market cap of $146.22 billion, a PE ratio of 317.32, a P/E/G ratio of 0.71 and a beta of 0.21. The business has a fifty day moving average of $99.61 and a 200 day moving average of $91.62. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $118.42. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.69%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley increased their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.24.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.